TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Alvotech ( (ALVO) ) is now available.
On November 12, 2025, Alvotech announced its financial results for the first nine months of 2025, reporting a 24% increase in total revenues to $420 million compared to the previous year. Despite a decrease in adjusted EBITDA by 21% due to increased R&D investments, the company revised its full-year revenue outlook to $570-$600 million, anticipating strong growth driven by new biosimilar approvals in Japan and Europe. Alvotech’s strategic focus on expanding its biosimilar portfolio and maintaining operational excellence positions it for continued growth, with significant product launches expected in Q4 2025 and beyond.
The most recent analyst rating on (ALVO) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Underperform.
Alvotech’s overall stock score is primarily impacted by its financial instability, with high leverage and declining revenue growth posing significant risks. Technical analysis further indicates bearish momentum, while valuation metrics suggest potential overvaluation. Despite strategic investments and growth potential, regulatory and operational challenges weigh heavily on the stock’s outlook.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a global biotech company specializing in the development and manufacture of biosimilar medicines, focusing on expanding patient access to quality biologics worldwide. The company holds a leading market position with its biosimilars, including Humira in the U.S. and Stelara in Europe, and is committed to pipeline expansion and commercialization efforts across key global markets.
Average Trading Volume: 514,250
Technical Sentiment Signal: Sell
Current Market Cap: $1.66B
For a thorough assessment of ALVO stock, go to TipRanks’ Stock Analysis page.